Migraine - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 185 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Migraine - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Migraine - Pipeline Review, H2 2014', provides an overview of the Migraine's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Migraine
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Migraine pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Migraine
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Migraine Overview 9
Therapeutics Development 10
Pipeline Products for Migraine - Overview 10
Pipeline Products for Migraine - Comparative Analysis 11
Migraine - Therapeutics under Development by Companies 12
Migraine - Therapeutics under Investigation by Universities/Institutes 16
Migraine - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Migraine - Products under Development by Companies 21
Migraine - Products under Investigation by Universities/Institutes 24
Migraine - Companies Involved in Therapeutics Development 25
Bristol-Myers Squibb Company 25
Allergan, Inc. 26
Amgen Inc. 27
Eli Lilly and Company 28
Questcor Pharmaceuticals, Inc. 29
BioDelivery Sciences International, Inc. 30
Nektar Therapeutics 31
Merck & Co., Inc. 32
TheraJect, Inc. 33
Biofrontera AG 34
Astellas Pharma Inc. 35
Pfizer Inc. 36
Vertex Pharmaceuticals Incorporated 37
Impax Laboratories, Inc. 38
Revance Therapeutics, Inc. 39
IntelGenx Corp. 40
Avanir Pharmaceuticals, Inc. 41
Paladin Labs Inc. 42
Transcept Pharmaceuticals, Inc. 43
Pozen, Inc. 44
D-Pharm Ltd. 45
Ache Laboratorios Farmaceuticos S/A 46
Alder Biopharmaceuticals Inc. 47
CoLucid Pharmaceuticals, Inc. 48
Charleston Laboratories, Inc. 49
Pantarhei Bioscience BV 50
NeurAxon, Inc. 51
Noxxon Pharma AG 52
Monosol Rx, LLC 53
Shin Nippon Biomedical Laboratories, Ltd. 54
Medestea Research & Production S.p.A. 55
Proreo Pharma AG 56
Heptares Therapeutics Ltd. 57
iCeutica, Inc. 58
Trigemina, Inc. 59
Istituto Italiano di Tecnologia 60
Northern Light Pharmaceuticals AB 61
Migraine - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Target 64
Assessment by Mechanism of Action 68
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
dihydroergotamine mesylate - Drug Profile 76
rizatriptan benzoate - Drug Profile 79
(sumatriptan succinate + naproxen sodium) - Drug Profile 81
(naproxen sodium + naratriptan hydrochloride) - Drug Profile 83
sumatriptan succinate - Drug Profile 84
sumatriptan succinate - Drug Profile 86
sumatriptan succinate - Drug Profile 88
RT-001 - Drug Profile 89
oxytocin - Drug Profile 91
LY-2951742 - Drug Profile 92
lasmiditan succinate - Drug Profile 93
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 95
corticotropin - Drug Profile 97
rimegepant - Drug Profile 99
ALD-403 - Drug Profile 101
ubrogepant - Drug Profile 103
AMG-334 - Drug Profile 104
PP-012 - Drug Profile 105
LBR-101 - Drug Profile 106
CLH-1T - Drug Profile 108
histamine dihydrochloride - Drug Profile 109
ELSM-11 - Drug Profile 110
BF-1 - Drug Profile 111
(estrogen + progesterone) - Drug Profile 112
NXN-462 - Drug Profile 114
DP-VPA - Drug Profile 115
PF-05180999 - Drug Profile 117
zolmitriptan - Drug Profile 118
IPX-232 - Drug Profile 119
AMG-333 - Drug Profile 120
Small Molecule to Inhibit nNOS/NET for Migraine - Drug Profile 121
BEMA Triptan - Drug Profile 122
DIS-COM-TRO - Drug Profile 123
NKTR-192 - Drug Profile 124
ICE-1209 - Drug Profile 125
ICE-1210 - Drug Profile 126
ICE-1211 - Drug Profile 127
sumatriptan succinate - Drug Profile 128
rizatriptan benzoate - Drug Profile 129
(rizatriptan benzoate + ondansetron hydrochloride) - Drug Profile 130
Small molecule to Inhibit CGRP for Migraine - Drug Profile 131
Deina - Drug Profile 132
Tribarcina - Drug Profile 133
Small Molecule to Inhibit Prostaglandin E2 - Drug Profile 134
MK-8825 - Drug Profile 135
NOXL-41 - Drug Profile 136
Small Molecule to Activate GABA Receptor for Migraine - Drug Profile 137
DORA-12 - Drug Profile 138
dihydroergotamine mesylate - Drug Profile 139
URB-937 - Drug Profile 140
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 141
SST-8055 - Drug Profile 142
BCIBUMG-006 - Drug Profile 143
AA-71 - Drug Profile 144
Protein to Activate IGF-1 Receptor for Migraine - Drug Profile 145
Small Molecules to Inhibit CGRP Receptor for Migraine - Drug Profile 146
Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile 147
ELS-110 - Drug Profile 148
Migraine - Recent Pipeline Updates 149
Migraine - Dormant Projects 170
Migraine - Discontinued Products 172
Migraine - Product Development Milestones 173
Featured News & Press Releases 173
Appendix 180
Methodology 180
Coverage 180
Secondary Research 180
Primary Research 180
Expert Panel Validation 180
Contact Us 181
Disclaimer 181

List of Tables
Number of Products under Development for Migraine, H2 2014 14
Number of Products under Development for Migraine - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Comparative Analysis by Late Stage Development, H2 2014 21
Comparative Analysis by Clinical Stage Development, H2 2014 22
Comparative Analysis by Early Stage Development, H2 2014 23
Comparative Analysis by Unknown Stage Development, H2 2014 24
Products under Development by Companies, H2 2014 25
Products under Development by Companies, H2 2014 (Contd..1) 26
Products under Development by Companies, H2 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2014 28
Migraine - Pipeline by Bristol-Myers Squibb Company, H2 2014 29
Migraine - Pipeline by Allergan, Inc., H2 2014 30
Migraine - Pipeline by Amgen Inc., H2 2014 31
Migraine - Pipeline by Eli Lilly and Company, H2 2014 32
Migraine - Pipeline by Questcor Pharmaceuticals, Inc., H2 2014 33
Migraine - Pipeline by BioDelivery Sciences International, Inc., H2 2014 34
Migraine - Pipeline by Nektar Therapeutics, H2 2014 35
Migraine - Pipeline by Merck & Co., Inc., H2 2014 36
Migraine - Pipeline by TheraJect, Inc., H2 2014 37
Migraine - Pipeline by Biofrontera AG, H2 2014 38
Migraine - Pipeline by Astellas Pharma Inc., H2 2014 39
Migraine - Pipeline by Pfizer Inc., H2 2014 40
Migraine - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 41
Migraine - Pipeline by Impax Laboratories, Inc., H2 2014 42
Migraine - Pipeline by Revance Therapeutics, Inc., H2 2014 43
Migraine - Pipeline by IntelGenx Corp., H2 2014 44
Migraine - Pipeline by Avanir Pharmaceuticals, Inc., H2 2014 45
Migraine - Pipeline by Paladin Labs Inc., H2 2014 46
Migraine - Pipeline by Transcept Pharmaceuticals, Inc., H2 2014 47
Migraine - Pipeline by Pozen, Inc., H2 2014 48
Migraine - Pipeline by D-Pharm Ltd., H2 2014 49
Migraine - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2014 50
Migraine - Pipeline by Alder Biopharmaceuticals Inc., H2 2014 51
Migraine - Pipeline by CoLucid Pharmaceuticals, Inc., H2 2014 52
Migraine - Pipeline by Charleston Laboratories, Inc., H2 2014 53
Migraine - Pipeline by Pantarhei Bioscience BV, H2 2014 54
Migraine - Pipeline by NeurAxon, Inc., H2 2014 55
Migraine - Pipeline by Noxxon Pharma AG, H2 2014 56
Migraine - Pipeline by Monosol Rx, LLC, H2 2014 57
Migraine - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H2 2014 58
Migraine - Pipeline by Medestea Research & Production S.p.A., H2 2014 59
Migraine - Pipeline by Proreo Pharma AG, H2 2014 60
Migraine - Pipeline by Heptares Therapeutics Ltd., H2 2014 61
Migraine - Pipeline by iCeutica, Inc., H2 2014 62
Migraine - Pipeline by Trigemina, Inc., H2 2014 63
Migraine - Pipeline by Istituto Italiano di Tecnologia, H2 2014 64
Migraine - Pipeline by Northern Light Pharmaceuticals AB, H2 2014 65
Assessment by Monotherapy Products, H2 2014 66
Assessment by Combination Products, H2 2014 67
Number of Products by Stage and Target, H2 2014 70
Number of Products by Stage and Mechanism of Action, H2 2014 74
Number of Products by Stage and Route of Administration, H2 2014 77
Number of Products by Stage and Molecule Type, H2 2014 79
Migraine Therapeutics - Recent Pipeline Updates, H2 2014 153
Migraine - Dormant Projects, H2 2014 174
Migraine - Discontinued Products, H2 2014 176